Only age itself proved a stronger predictor of death
A study from New York University Langone Medical Center, published in JAMA Psychiatry in January 2021, revealed that people living with schizophrenia who contracted Covid-19 were 2.7 times more likely to die than those without psychiatric illness — a risk surpassed only by age itself. Drawing on nearly 7,400 cases across New York's first pandemic wave, researchers found no direct biological mechanism to explain the disparity, pointing instead toward something older and more troubling: a healthcare system that has long failed its most vulnerable. The virus did not single out schizophrenia — it found people already made fragile by neglect, inequality, and accumulated medical disadvantage.
- Among all measurable risk factors for Covid-19 death, schizophrenia ranked second only to age — a finding that stunned even the researchers who uncovered it.
- The 75 schizophrenia patients in the study carried into their infections a hidden burden: undiagnosed heart disease, uncontrolled diabetes, and metabolic damage caused by the very antipsychotic medications meant to help them.
- Experts warn that discrimination in clinical settings means schizophrenia patients routinely have their physical complaints dismissed, delaying care at precisely the moments it matters most.
- The pandemic has forced a reckoning — calls are growing for specialized care pathways that treat severe mental illness not as a footnote but as a primary medical vulnerability during health crises.
- What the data ultimately reflects is not a viral mystery but a systemic one: elevated mortality as the measurable consequence of decades of medical abandonment.
In late January 2021, a study published in JAMA Psychiatry delivered a striking finding: among all the risk factors researchers examined for Covid-19 death, only age proved more predictive than schizophrenia. Patients with the condition were 2.7 times more likely to die after contracting the virus than those without psychiatric illness.
The research drew on health records from 260 clinics and four hospitals across New York, tracking 7,348 adults who tested positive during the pandemic's first wave. Of those, 75 had a documented history of schizophrenia. Within 45 days of diagnosis, 864 patients across the full cohort had died or entered hospice care — and the mortality signal for schizophrenia was unmistakable. Mood and anxiety disorders, by contrast, showed no significant correlation with worse outcomes.
Schizophrenia carries its own grim baseline: people living with it already die two to three years earlier than the general population. But researchers found no obvious biological mechanism by which the illness would make Covid more lethal. The explanation, experts suggested, was systemic rather than cellular.
Dr. Soumitra Pathare, a Pune-based psychiatrist, pointed to chronic neglect in physical healthcare — patients whose complaints are routinely dismissed, who rarely receive standard screenings, and who face discrimination when seeking care. The antipsychotic medications used to manage schizophrenia are themselves known to trigger metabolic syndrome, quietly elevating the risk of diabetes and cardiovascular disease. By the time these patients encountered Covid-19, many were already medically fragile in ways that had gone unaddressed for years.
The study's authors called for targeted care pathways for people with severe mental illness during health emergencies. But the deeper implication was harder to contain: the pandemic had not created this vulnerability — it had simply made it visible. Elevated mortality among schizophrenia patients was less a medical mystery than a mirror held up to the quiet, persistent failures of a healthcare system that had never fully made room for them.
A study published in JAMA Psychiatry in late January 2021 found something stark: people with schizophrenia who contracted Covid-19 were nearly three times as likely to die as Covid patients without psychiatric illness. Among all the risk factors researchers examined—age, underlying medical conditions, demographic markers—only age itself proved a stronger predictor of death.
The research came from New York University Langone Medical Center, drawing on health records from 260 clinics and four hospitals across New York during the pandemic's first wave. Between early March and the end of May 2020, researchers tracked 7,348 adults who tested positive for the coronavirus. Of those, 75 had a documented history of schizophrenia, 564 had mood disorders, and 360 had anxiety disorders. Within 45 days of a positive test, 864 patients died or were discharged to hospice care. The association was unmistakable for schizophrenia: a 2.7-fold increase in mortality risk. Mood and anxiety disorders showed no significant correlation with worse Covid outcomes.
Schizophrenia is a chronic neurological condition marked by distorted thinking and perception—delusions, hallucinations, disorganized speech, loss of motivation. People living with it already face a grim baseline: they die two to three years earlier than the general population. The question the researchers grappled with was why Covid amplified this disparity so dramatically. The magnitude of the increase surprised even the study authors. Schizophrenia itself has no obvious direct biological mechanism that would make the virus more lethal. So what was happening?
Dr. B.N. Gangadhar, director of India's National Institute of Mental Health and Neuro Sciences, offered one explanation: schizophrenia accelerates the aging process at the cellular level. Any chronic illness layered onto Covid compounds the risk. But other experts pointed to something less biological and more systemic. Dr. Soumitra Pathare, a psychiatrist at Pune's Indian Law Society, suggested the real culprit was neglect. People with schizophrenia, he explained, are routinely overlooked in healthcare settings. They don't receive regular physical health screenings. They face discrimination when seeking medical care. Their complaints are dismissed or minimized. The medications used to treat schizophrenia itself—antipsychotics—are known to trigger metabolic syndrome, increasing the likelihood of diabetes and other conditions that make Covid more dangerous.
The picture that emerged was one of accumulated disadvantage. Patients with schizophrenia arrive at a Covid infection already burdened: undiagnosed heart disease, uncontrolled diabetes, poor nutrition, medication side effects that destabilize their metabolism. They may delay seeking treatment because they distrust healthcare systems or lack access to care. They may struggle to communicate their symptoms clearly. The virus doesn't kill them because of schizophrenia itself, but because schizophrenia has left them medically fragile and socially isolated, moving through a healthcare system that has never fully included them.
The study's authors called for targeted interventions—specialized care pathways for people with severe mental illness during health crises. But the deeper implication was harder to ignore: the pandemic had exposed how thoroughly people with schizophrenia are abandoned by ordinary medicine. Their elevated mortality from Covid was not a medical mystery. It was a mirror held up to healthcare inequality.
Notable Quotes
The high risk of mortality associated with schizophrenia spectrum diagnoses ranks second behind age in strength of association among all demographic and medical risk factors examined— JAMA Psychiatry study
People with schizophrenia end up getting neglected in healthcare; they don't get their physical health checked regularly, and there is evidence of discrimination in physical healthcare provisions— Dr. Soumitra Pathare, psychiatrist and director of Centre for Mental Health Law and Policy
The Hearth Conversation Another angle on the story
Why would a psychiatric condition make someone more vulnerable to a respiratory virus? Is there something about schizophrenia itself that weakens the immune system?
That's the question the researchers expected to answer, but it turned out to be more complicated. The virus doesn't care about psychiatric diagnosis. What matters is what comes with it—the untreated diabetes, the heart problems nobody caught, the medications that destabilize metabolism.
So it's not the schizophrenia. It's everything else.
Exactly. But that "everything else" isn't random. It's what happens when you're a person with schizophrenia moving through a healthcare system that doesn't really see you. You skip appointments because you can't navigate the system. Doctors don't listen carefully. You don't get your blood pressure checked regularly.
The study found 75 people with schizophrenia among 7,348 positive cases. That's less than one percent. Does that mean it's rare?
It means schizophrenia is rare in the general population—about one percent. But among those 75, the death rate was catastrophic compared to everyone else. That's the point. It's a small group bearing an enormous burden.
What would targeted interventions actually look like?
Probably dedicated care teams. Someone checking in regularly. Making sure medications are taken. Screening for the conditions that compound the risk. Treating people with schizophrenia like they matter during a crisis—which, the data suggests, wasn't happening.
Does this change how we should think about mental illness and physical health?
It should. It shows that the separation we make between mental and physical health is artificial and dangerous. Schizophrenia isn't just a psychiatric problem. It's a health problem, full stop. And if we ignore the physical side, people die.